Patents by Inventor Stephen Michael Kelsey

Stephen Michael Kelsey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MESSENGER RIBONUCLEIC ACIDS FOR THE PRODUCTION OF INTRACELLULAR BINDING POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20210206818
    Abstract: The invention features isolated mRNAs encoding at least one intracellular binding domain, including mRNAs comprising one or more modified nucleobase and preferably lacking an encoded scaffold polypeptide, and methods of using the same, for example, for inducing apoptosis and/or treating cancer (e.g., liver cancer or colorectal cancer).
    Type: Application
    Filed: January 20, 2017
    Publication date: July 8, 2021
    Inventors: Eric Yi-Chun HUANG, Joshua P. FREDERICK, Kristine MCKINNEY, Christina HENDERSON, Kahlin CHEUNG-ONG, Joseph BOLEN, Stephen Michael KELSEY, Michael MORIN, Sushma GURUMURTHY, Kerry BENENATO, Stephen HOGE, Iain MCFADYEN, Vladimir PRESNYAK
  • MESSENGER RIBONUCLEIC ACIDS FOR THE PRODUCTION OF INTRACELLULAR BINDING POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20190119357
    Abstract: The invention features isolated mRNAs encoding fusion polypeptides comprising a Stefm A (SteA) scaffold polypeptide and one or more binding polypeptides, such as one or more Bc1-2 homology 3 (BH3) domains, including mRNAs comprising one or more modified nucleobase, and methods of using the same, for example, for inducing apoptosis and/or treating cancer (e.g., liver cancer or colorectal cancer).
    Type: Application
    Filed: July 22, 2016
    Publication date: April 25, 2019
    Inventors: Eric Yi-chun HUANG, Josh FREDERICK, Kristine MCKINNEY, Christina HENDERSON, Kahlin CHEUNG-ONG, Joseph BOLEN, Stephen Michael KELSEY, Michael MORIN, Sushma GURUMURTHY
  • Methods for Identifying Tumors That are Responsive to Treatement With Anti-ErbB2 Antibodies
    Publication number: 20110117096
    Abstract: Tumors are identified as responsive to treatment with anti-HER2 antibodies by detecting the presence of a HER2/HER3 and/or HER2/HER1 protein complex or for HER2 phosphorylation in a sample of tumor cells. Patients suffering from a tumor comprising HER/2/HER1 and/or HER2/HER3 heterodimers and/or HER2 phosphorylation are treated with anti-HER2 antibodies, such as rhuMAb 2C4.
    Type: Application
    Filed: November 29, 2010
    Publication date: May 19, 2011
    Inventors: BIRGIT BOSSENMAIER, HANS-JOACHIM MÜLLER, HANS KOLL, MARK X. SLIWKOWSKI, STEPHEN MICHAEL KELSEY
  • Methods for identifying tumors that are responsive to treatment with anti-ErbB2 antibodies
    Publication number: 20040106161
    Abstract: Tumors are identified as responsive to treatment with anti-HER2 antibodies by detecting the presence of a HER2/HER3 and/or HER2/HER1 protein complex or for HER2 phosphorylation in a sample of tumor cells. Patients suffering from a tumor comprising HER/2/HER1 and/or HER2/HER3 heterodimers and/or HER2 phosphorylation are treated with anti-HER2 antibodies, such as rhuMAb 2C4.
    Type: Application
    Filed: July 14, 2003
    Publication date: June 3, 2004
    Inventors: Birgit Bossenmaier, Hans-Joachim Muller, Hans Koll, Mark X. Sliwkowski, Stephen Michael Kelsey